Allergens displayed on virus‐like particles are highly immunogenic but fail to activate human mast cells

The goal of allergen‐specific immunotherapy is the induction of protective immune responses in the absence of anaphylactic reactions. We have previously shown that Fel d 1, the major cat allergen, displayed in a repetitive fashion on virus‐like particles (VLPs) may fulfill these criteria. Specifically, Fel d 1 on VLPs induced strongly increased protective IgG responses compared to free allergen in mice while anaphylactic reactions were essentially abolished. Here we extend these findings to human mast cells and offer a mechanistic explanation for the reduced anaphylactic activity.

[1]  T. Kündig,et al.  Allergen‐specific immunotherapy: is it vaccination against toxins after all? , 2017, Allergy.

[2]  R. Van Ree,et al.  International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.

[3]  P. Sowa,et al.  Allergic diseases: the price of civilisational progress , 2014, Postepy dermatologii i alergologii.

[4]  T. Kündig,et al.  Virus-induced humoral immunity: on how B cell responses are initiated. , 2013, Current opinion in virology.

[5]  M. Huber.  Activation/Inhibition of mast cells by supra-optimal antigen concentrations , 2013, Cell Communication and Signaling.

[6]  M. Vogel,et al.  Accelerated Disassembly of IgE:Receptor Complexes by a Disruptive Macromolecular Inhibitor , 2012, Nature.

[7]  T. Kündig,et al.  Mechanisms of allergen-specific desensitization. , 2010, The Journal of allergy and clinical immunology.

[8]  B. Lanier,et al.  Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. , 2009, The Journal of allergy and clinical immunology.

[9]  D. Metcalfe,et al.  Mechanisms of mast cell signaling in anaphylaxis. , 2009, The Journal of allergy and clinical immunology.

[10]  M. Bachmann,et al.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy , 2009, The Journal of experimental medicine.

[11]  D. MacGlashan.  IgE receptor and signal transduction in mast cells and basophils. , 2008, Current opinion in immunology.

[12]  H. Hoffmann,et al.  Comparison of short term in vitro cultured human mast cells from different progenitors - Peripheral blood-derived progenitors generate highly mature and functional mast cells. , 2008, Journal of immunological methods.

[13]  H. Hoffmann,et al.  Seven week culture of functional human mast cells from buffy coat preparations. , 2008, Journal of immunological methods.

[14]  Stephen J. Galli,et al.  The development of allergic inflammation , 2008, Nature.

[15]  B. Sutton,et al.  IgE in allergy and asthma today , 2008, Nature Reviews Immunology.

[16]  G. Lipowsky,et al.  Regulation of IgG antibody responses by epitope density and CD21‐mediated costimulation , 2002, European journal of immunology.

[17]  P. Pumpens,et al.  Mutilation of RNA phage Qβ virus‐like particles: from icosahedrons to rods , 2000, FEBS letters.

[18]  T. Kawakami,et al.  Akt-Dependent Cytokine Production in Mast Cells , 2000, Journal of Experimental Medicine.

[19]  G. Watt,et al.  Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring , 2000, BMJ : British Medical Journal.

[20]  A. Nisonoff,et al.  Clearance of IgE from serum of normal and hybridoma-bearing mice. , 1985, Journal of immunology.

[21]  H. Hoffmann.  Generation of a human allergic mast cell phenotype from CD133(+) stem cells. , 2014, Methods in molecular biology.

[22]  M. Tsai,et al.  Mast cells as "tunable" effector and immunoregulatory cells: recent advances. , 2005, Annual review of immunology.